THSD7A and cancer: THSD7A is a second antigenic target for idiopathic MN; it was identified in 2014, followed by the first discovery of PLA2R.[2] The prevalence of THSD7A-associated MN in idiopathic MN is reportedly 3 to 9% in Japan and is supposed to be higher than that in western countries.[9,10] Moreover, THSD7A-associated MN is reported to often be associated with malignancies.[11] Some studies have reported THSD7A-associated MN to be related to allergic diseases, especially asthma, or eosinophilia.[12,13] In our patient, detailed and repeated examination did not detect malignancies or allergic diseases.